Latest news with #HQY
Yahoo
3 days ago
- Business
- Yahoo
HealthEquity (NASDAQ:HQY) delivers shareholders respectable 12% CAGR over 5 years, surging 3.4% in the last week alone
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, while the HealthEquity, Inc. (NASDAQ:HQY) share price is up 77% in the last five years, that's less than the market return. Some buyers are laughing, though, with an increase of 33% in the last year. The past week has proven to be lucrative for HealthEquity investors, so let's see if fundamentals drove the company's five-year performance. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the five years of share price growth, HealthEquity moved from a loss to profitability. That's generally thought to be a genuine positive, so investors may expect to see an increasing share price. You can see below how EPS has changed over time (discover the exact values by clicking on the image). We know that HealthEquity has improved its bottom line over the last three years, but what does the future have in store? Take a more thorough look at HealthEquity's financial health with this free report on its balance sheet. A Different Perspective We're pleased to report that HealthEquity shareholders have received a total shareholder return of 33% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 12% per year), it would seem that the stock's performance has improved in recent times. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for HealthEquity you should know about. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-07-2025
- Business
- Yahoo
HealthEquity (HQY) is a Top-Ranked Growth Stock: Should You Buy?
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth. Draper, UT-headquartered HealthEquity provides integrated solutions for healthcare account management, health reimbursement arrangement and flexible spending accounts for health plans, insurance companies and third-party administrators in the United States. HQY sits at a Zacks Rank #2 (Buy), holds a Growth Style Score of B, and has a VGM Score of B. Earnings and sales are forecasted to increase 19.6% and 8.5% year-over-year, respectively. Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.11 to $3.73 per share. HQY also boasts an average earnings surprise of 12.4%. HealthEquity is also cash rich. The company has generated cash flow growth of 19.3%, and is expected to report cash flow expansion of 25.9% in 2026. HQY should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HealthEquity, Inc. (HQY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-07-2025
- Business
- Yahoo
GDRX vs. HQY: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits. Currently, GoodRx Holdings, Inc. has a Zacks Rank of #2 (Buy), while HealthEquity has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that GDRX has an improving earnings outlook. But this is just one factor that value investors are interested in. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value. GDRX currently has a forward P/E ratio of 12.80, while HQY has a forward P/E of 27.57. We also note that GDRX has a PEG ratio of 1.15. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. HQY currently has a PEG ratio of 1.32. Another notable valuation metric for GDRX is its P/B ratio of 2.64. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, HQY has a P/B of 4.2. These metrics, and several others, help GDRX earn a Value grade of B, while HQY has been given a Value grade of D. GDRX stands above HQY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that GDRX is the superior value option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
26-06-2025
- Business
- Yahoo
Here's Why HealthEquity (HQY) is a Strong Growth Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth. Draper, UT-headquartered HealthEquity provides integrated solutions for healthcare account management, health reimbursement arrangement and flexible spending accounts for health plans, insurance companies and third-party administrators in the United States. HQY boasts a Growth Style Score of A and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 18.6% year-over-year for 2026, while Wall Street anticipates its top line to improve by 8.2%. Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.08 to $3.70 per share. HQY also boasts an average earnings surprise of 12.4%. HealthEquity is also cash rich. The company has generated cash flow growth of 19.3%, and is expected to report cash flow expansion of 25.9% in 2026. With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, HQY should be on investors' short lists. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HealthEquity, Inc. (HQY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
02-06-2025
- Business
- Forbes
How Will HealthEquity Stock React To Its Upcoming Earnings?
POLAND - 2025/02/14: In this photo illustration, the HealthEquity Inc company logo is seen displayed ... More on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) HealthEquity (NASDAQ:HQY), a custodian for health savings accounts, is set to announce its earnings on Tuesday, June 3, 2025. Historically, the stock has demonstrated a strong likelihood of positive returns following its earnings announcements. Over the last five years, HQY has experienced a positive one-day return after earnings in 70% of cases, with a median increase of 3.4% and a peak one-day rise of 11.6%. For traders focused on events, understanding these historical trends can be beneficial, although actual results will significantly impact stock performance. There are two main strategies to consider: Analysts expect HealthEquity to report earnings of $0.81 per share on revenue of $322 million. This is an increase compared to the previous year's quarter, which recorded earnings of $0.80 per share on revenue of $288 million. From a fundamental view, HealthEquity currently boasts a market capitalization of $8.7 billion. Over the past twelve months, the company generated $1.2 billion in revenue and was operationally profitable, reporting $203 million in operating profits and a net income of $97 million. Therefore, if you are looking for growth with lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative—having outperformed the S&P 500 and delivering returns exceeding 91% since its inception. Additionally, see – Buy, Sell, or Hold HIMS Stock? View earnings reaction history of all stocks Some insights on one-day (1D) post-earnings returns: Additional data for 5-Day (5D) and 21-Day (21D) returns observed post-earnings are summarized along with the statistics in the table below. HQY 1D, 5D, and 21D Post-Earnings Return A relatively less risky strategy (although not effective if the correlation is low) involves understanding the correlation between short-term and medium-term returns following earnings, identifying a pair with the highest correlation, and executing the appropriate trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a 'long' position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns. HQY Correlation Between 1D, 5D, and 21D Historical Returns Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a combination of all three: the S&P 500, S&P mid-cap, and Russell 2000), delivering strong returns for investors. Furthermore, if you're seeking upside with a more stable performance than an individual stock like HealthEquity, consider the High Quality portfolio, which has outperformed the S&P and achieved returns greater than 91% since its inception.
